[Skip to Navigation]
November 1994

Ganciclovir Intraocular Device and Patient Survival

Author Affiliations

Sydney, Australia

Arch Ophthalmol. 1994;112(11):1404. doi:10.1001/archopht.1994.01090230014002

The problem of patient survival when ganciclovir is given only locally for the treatment of cytomegalovirus retinitis is a concern of physicians treating this disease and was the subject of correspondence in the January 1994 issue of the Archives.1,2 We agree with the findings of Anand et al3 that local treatment can effectively control cytomegalovirus retinitis,4 and we have found that this does not appear to reduce patient survival.

Using high-dose intravitreal ganciclovir (2 mg/0.1 mL) exclusively on a weekly basis, we found that after a 100% initial response to the treatment, retinitis recurred in only six (17%) of 35 eyes (in four eyes [12%] if noncompliant patients are excluded) at a median survival of 42 weeks. Furthermore, the median survival time for this group of patients did not seem to be adversely affected by the lack of systemic therapy. Our 22 patients survived a median of

Add or change institution